Sarcoma Surgical Oncology Orthopedics
The University of Colorado Cancer Center has recruited Steven Thorpe, MD, FACS, a renowned orthopedic surgical oncologist and a sarcoma and limb-salvage specialist, to join the Department of Orthopedics at the CU School of Medicine as the new chief of the musculoskeletal oncology program.
Building upon her previous research on the role of transcription factor SIX1 in sarcoma progression, Heide Ford, PhD, associate director of basic research at the University of Colorado Cancer Center, recently published a paper, in collaboration with CU Cancer Center members Paul Jedlicka, MD, and Jim Costello, PhD, in the journal Nature Communications showing that SIX1 plays a very different role in Ewing sarcoma than it does in other sarcomas — the general term for a broad group of cancers that can form in various locations in the body, including the bones and the soft tissue that connects, supports, and surrounds other body structures.
Research Pediatric Cancer Sarcoma Radiation
For many pediatric cancer patients and their families, “scanxiety” is a very real and very scary feeling – the worry that can precede scans before treatment, and the uncertainty stemming from scans after treatment is completed.
Some 100 researchers from around the world were in Aurora last week to discuss the latest findings and news around Kaposi sarcoma herpesvirus (KSHV), the virus that causes a type of cancer known as Kaposi sarcoma.
Research Patient Care Sarcoma Clinical Trials
Ward McNeilly thought he was a goner.
It was summer 2021, and the sarcoma that had started in the Denver resident’s left thigh seemed to be under control, subdued by radiation and chemotherapy following a surgery in 2018 to remove the initial tumor and another surgery in 2019 to remove cancerous tumors in his groin. McNeilly was doing so well, in fact, that his doctors at UCHealth University of Colorado Hospital authorized a “chemo vacation” to give his body a break from some of the side effects of the treatment.
Research Community Pediatric Cancer Sarcoma
In normal human development, the SIX1 gene is critical for embryonic muscle development. After a person is born and as they mature, SIX1 is downregulated, or becomes less prevalent in cells.
Patient Care Community Sarcoma
The cancer diagnosis came at a time when it seemed as though everything was happening – he was only 37 and soon to become president of the Denver City Council; his three children were ages 4, 6, and 9; he had just run the BOLDERBoulder 10K.
A new movie streaming on Disney+ is shining a spotlight on a rare type of bone cancer that occurs most often in children and young adults.
Research Sarcoma Cancer Bone Cancer
Video Transcript:
Good morning, I’m Dr. Breelyn Wilky from the sarcoma program at the University of Colorado Cancer Center.
While many cancer types have added new treatments including genetically targeted drugs and immunotherapies, treatment for the rare types of cancer known as sarcomas have remained largely the same for about two decades. Now, two grants to University of Colorado Cancer Center researchers from the Sarcoma Foundation of America hope to change this.
After five years as an assistant professor at the University of Miami treating sarcoma patients and running sarcoma clinical trials, Breelyn Wilky, MD, recently joined University of Colorado Cancer Center as Deputy Associate Director for Clinical Research. Here we speak with Wilky about what drew her to Colorado and what’s next for the treatment of sarcoma.
I met Ben Walburn at 4:00am on a slushy spring morning four years ago in a Boulder parking lot outside the house of a mutual friend, Adam. It was still dark and clouds spit little wet icicles as Ben and I huddled by our cars in the glow of headlamps, blowing steam off insulated coffee cups while trying to raise Adam via text. The plan was to exploit Adam’s birthday as an excuse for a weekend rock-climbing trip somewhere dryer and warmer – was it Escalante or maybe it was Penitente? Finally, Adam texted back: His young kids had gotten sick overnight and he had to bail. Without Adam, the trip fell apart. Ben and I made vague plans to climb together at some point, but it never seemed to come together. He was in his early 40s, I was in my late 30s, and we were both busy. Besides, it wasn’t pressing – we had all the time in the world to make it happen.
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.
Mark Harden
